Rahul Banerjee: Safety and Activity of Talquetamab in Patients with Relapsed or Refractory Multiple Myeloma
Rahul Banerjee, Assistant Professor at Fred Hutchinson Cancer Center at the University of Washington, posted on X:
“Nice less is more tidbit from MonumenTAL-1 in Multiple Myeloma I hadn’t noticed before.
We know from ASH24 TAL-1 cohort (Ajai Chari et al) that talquetamab dose reduction after response preserves efficacy, decreased most AEs.
Suppl Fig from OG trial: landmarked at D300? better PFS as well!
Many caveats: Small n (48 dose-reduced vs 157 not), not randomized. BUT landmarking after 10 cycles removes some biases.
This isn’t so hard for me to believe: less frequent dosing less AEs, possibly increase T-cell exhaustion?”
Title: Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1–2 study
Authors: Ajai Chari, Cyrille Touzeau, Carolina Schinke, Monique C Minnema, Jesus G Berdeja, Albert Oriol, Niels W C J van de Donk, Paula Rodríguez-Otero, Daniel Morillo, Carmen Martinez-Chamorro, María-Victoria Mateos, Luciano J Costa, Jo Caers, Leo Rasche, Amrita Krishnan, Jing Christine Ye, Lionel Karlin, Brea Lipe, Deeksha Vishwamitra, Sheri Skerget, Raluca Verona, Xuewen Ma, Xiang Qin, Hein Ludlage, Michela Campagna, Tara Masterson, Brandi Hilder, Jaszianne Tolbert, Thomas Renaud, Jenna D Goldberg, Colleen Kane, Christoph Heuck, Jesus San-Miguel, Philippe Moreau
Read The Full Article at The Lancet Hematology.
More posts featuring Rahul Banerjee on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023